In a tense moment during a Senate confirmation hearing, President Donald Trump’s nominee to lead the Food and Drug Administration (FDA) faced sharp scrutiny over her stance on birth control. Heidi Overton, a physician and domestic policy adviser, struggled to provide clear answers regarding whether intrauterine devices (IUDs) are considered abortifacients, leaving Senator Patty Murray (D-WA) visibly frustrated.
The exchange unfolded on Thursday before the Senate Health, Education, Labor, and Pensions Committee, where Overton was being evaluated for her potential role as FDA commissioner. Murray, a senior Democrat on the committee, pressed Overton on an important issue as time ran out for her questioning.
“Last year, the Trump administration falsely labeled birth control as abortion. Do you agree that, say, an IUD is an abortifacient?” Murray asked pointedly.
Overton’s response was evasive. “Senator, if I have the privilege of being confirmed, first off, I commit to working with you on the food safety pillars that are critically important,” she replied, seemingly sidestepping the question.
Murray interjected, determined for clarity: “I appreciate that. But I wanted to know if you agree that an IUD is an abortifacient.” This time, Overton maintained her stance on remaining general until confirmation, stating, “If I’m confirmed as FDA commissioner, I’ll be fully briefed in all their prior decisions and make determinations according to the standards of safety and efficacy.”
This exchange marked a pivotal moment for the hearing, illustrating a growing division on reproductive health issues within the Senate and the broader political landscape. The silence that followed Overton’s answer led to a growing sense of incredulity among observers, including Murray, who found herself unsure how to respond.
“I don’t think you answered the question,” Murray finally said, glancing over at the committee’s chair, Senator Bill Cassidy (R-LA), for support.
Referring to Overton’s potential confirmation as FDA chief, Murray expressed alarm: “I think it is outrageous and should be deeply alarming to all Americans right now that the prospect of an FDA commissioner who doesn’t know that birth control is not an abortion is deeply concerning to me.”
This controversy traces its roots back to broader policy decisions made during the Trump administration, particularly in 2025, when the U.S. Agency for International Development announced plans to destroy $10 million in contraceptives intended for foreign aid recipients.
The agency justified its actions by declaring, “President Trump is committed to protecting the lives of unborn children all around the world. The administration will no longer supply abortifacient birth control under the guise of foreign aid.”
Among the contraceptives slated for destruction were IUDs, hormonal implants, and birth control pills, prompting outrage from public health advocates.
Jessica Valenti, a noted journalist, reported these developments extensively, highlighting the adverse effects of such policies on women’s health both domestically and internationally.
The American College of Obstetricians and Gynecologists emphasized the scientific consensus, stating, “By definition, contraceptives prevent pregnancy—not end a pregnancy. IUDs and other forms of birth control do not cause abortion, and any suggestion otherwise is misinformation.”
If confirmed, Overton would lead the FDA at a time when the agency is also reviewing the safety and efficacy of mifepristone, the abortion pill. Reports have indicated that she holds a critical view of the drug, previously labeling it “dangerous to women.”
Overton’s nomination reflects broader ideological battles over reproductive rights in the U.S., and her confirmation could have lasting impacts on how the FDA regulates contraceptives and abortion-related medications.
The tension between Murray and Overton during the hearing underscores a contentious climate surrounding reproductive health issues in America, as advocates on both sides brace for potential changes that could emerge from the FDA under Overton’s leadership.
As the confirmation process unfolds, all eyes will remain on the Senate, where debates over Overton’s qualifications and understanding of women’s health issues continue to captivate a divided nation.
The outcomes of these hearings may not only influence the future of the FDA but also signal whether the contentious climate around reproductive rights will see further escalation in the years to come.
